Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Alzheimerâ€™s disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28716
Licensor and Licensee are each pursuing various aspects of research in the field of Apheresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of the Pathophysiologic Basis of Diseases such as Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes.
IPSCIO Record ID: 316237
The Trust is the charitable remainder beneficiary that generates a potential income stream from donors, or other beneficiaries, to benefit the research of ALS.
Amyotrophic lateral sclerosis or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease.
Licensee is biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases that includes Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrigâ€™s disease.
IPSCIO Record ID: 7002
the Applications and the Patents; and
The Technology is owned by two entities that are under the control of the Chairman of our Board of Directors.
Licensor shall have sole discretion to select other countries into which exclusive rights in the Licensed technology may be pursued, and if we decline to pay those expenses, then licensor may pay said expenses and our Licensed rights in those countries will revert to the Licensor.
â€œApplicationsâ€ means PCT/US2009/062895, entitled Medication and Treatment for Disease.
â€œTrademarksâ€ mean Feldetrexâ„¢, including US Trademark Application
IPSCIO Record ID: 797
The grant of each License hereunder includes the right to grant subLicenses to Related Companies.
Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.
Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure). Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.
Licensee shall prominently use the Trademark on Licensed Products.
IPSCIO Record ID: 245714
'Nasal administration of foralumab is an innovative immunotherapy which has potential for treatment of neurodegenerative diseases such ALS and progressive MS'.
IPSCIO Record ID: 336372
Reagents shall mean biomarkers and protein targets developed and produced by Licensor for the diagnosis of congestive heart failure, insulin resistance, Alzheimerâ€™s disease, traumatic brain injury and other various diseases, excluding stroke. The term â€œReagentsâ€ shall also include all other biomarkers and protein targets developed and produced by Licensor (other than for stroke) for which there shall be application in the point of care diagnostic products.
POC Rapid Assays shall mean rapid assay diagnostic point of care products, utilizing Reagents; provided, however, that â€œPOC Rapid Assaysâ€ shall not include devices for test procedures performed in a hospitalâ€™s central clinical laboratory or in a reference laboratory setting. In addition, â€œPOC Rapid Assaysâ€ shall not include any assay that can be used on any instrument with random access capability and/or any instrument with the ability to analyze multiple samples.
POC Rapid Assay Specifications shall mean the standards and specifications for the manufacture of the POC Rapid Assays, as developed and agreed to by the Parties, as amended from time to time, and shall be appended to and form part of this Agreement.
Reagent Specifications shall mean the standards and specifications for the manufacture of the Reagents, as developed and agreed to by the Parties, as amended from time to time, and shall be appended to and form part of this Agreement.